Analgesics..
Acetaminophen
Aspirin
Ibuprofen
Indomethacin
Antiandrogens..
All
Proxalutamide
Spironolactone
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Diet
Exercise
Sleep
Sun
Melatonin
Metformin
Molnupiravir
Monoclonals..
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Vitamin A
Vitamin C
Vitamin D
Zinc
Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
Feedback
38 convalescent plasma COVID-19 controlled studies
5% increased risk, RR 1.05 [0.93-1.19]
c19
early.org/cp Jan 2023
Home
COVID-19 treatment studies for Convalescent Plasma
COVID-19 treatment studies for Conv. Plasma
C19 studies: Conv. Plasma
Conv. Plasma
Select treatment
Select treatment
Treatments
Treatments
Analgesics..
Acetaminophen
Meta
Aspirin
Meta
Ibuprofen
Meta
Indomethacin
Meta
Close
Lifestyle..
Diet
Meta
Exercise
Meta
Sleep
Meta
Sun
Meta
Close
Antiandrogens..
All
Meta
Proxalutamide
Meta
Spironolactone
Meta
Close
Melatonin
Meta
Bromhexine
Meta
Metformin
Meta
Budesonide
Meta
Molnupiravir
Meta
Cannabidiol
Meta
Monoclonals..
Bamlaniv../e..
Meta
Bebtelovimab
Meta
Casirivimab/i..
Meta
Sotrovimab
Meta
Tixagev../c..
Meta
Close
Colchicine
Meta
Nigella Sativa
Meta
Conv. Plasma
Meta
Nitazoxanide
Meta
Curcumin
Meta
Nitric Oxide
Meta
Ensovibep
Meta
Paxlovid
Meta
Famotidine
Meta
Peg.. Lambda
Meta
Favipiravir
Meta
Povidone-Iod..
Meta
Fluvoxamine
Meta
Quercetin
Meta
Hydroxychlor..
Meta
Remdesivir
Meta
Iota-carragee..
Meta
Vitamins..
Vitamin A
Meta
Vitamin C
Meta
Vitamin D
Meta
Close
Ivermectin
Meta
Zinc
Meta
Lactoferrin
Meta
Other Treatments
Global Adoption
Outcomes in COVID-19 convalescent plasma studies
Home
Share
Tweet
Studies
Studies
Global Adoption
Adoption
Submit Feedback
Feedback
Analgesics..
Acetaminophen
Aspirin
Ibuprofen
Indomethacin
Antiandrogens..
All
Proxalutamide
Spironolactone
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Diet
Exercise
Sleep
Sun
Melatonin
Metformin
Molnupiravir
Monoclonals..
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Vitamin A
Vitamin C
Vitamin D
Zinc
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
0
0.5
1
1.5+
All studies
-5%
38
25,816
Improvement, Studies, Patients
Relative Risk
Mortality
-5%
38
25,816
Ventilation
2%
14
2,626
ICU admission
-1%
5
2,072
Hospitalization
8%
11
3,044
Progression
7%
10
2,343
Recovery
0%
7
12,728
Viral clearance
25%
5
887
RCTs
1%
36
21,660
RCT mortality
1%
36
21,660
Peer-reviewed
1%
33
21,477
Early
-36%
5
1,508
Late
-4%
33
24,308
Convalescent Plasma for COVID-19
c19
early.org/cp Jan 2023
Favors
conv. plasma
Favors
control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Tau
2
= 0.49, I
2
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
-36% improvement
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
Improvement, RR [CI]
Treatment
Control
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
death
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
Gonzalez
-7%
1.07 [0.76-1.50]
death
60/130
26/60
OT
1
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
death
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
Bégin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CAPSID
Körper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
death
7/60
12/60
Raad
-240%
3.40 [2.29-5.02]
death
284 (n)
3,682 (n)
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
Tau
2
= 0.04, I
2
= 51.1%, p = 0.52
Late treatment
-4%
1.04 [0.92-1.18]
2,285/10,917
2,134/13,391
-4% improvement
All studies
-5%
1.05 [0.93-1.19]
2,298/11,670
2,144/14,146
-5% improvement
38 convalescent plasma COVID-19 studies
c19
early.org/cp Jan 2023
Tau
2
= 0.04, I
2
= 48.4%, p = 0.46
Effect extraction pre-specified
(most serious outcome)
1
OT: comparison with other treatment
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Libster (DB RCT)
50%
0.50 [0.09-2.65]
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
5/28
2/30
Korley (RCT)
-396%
4.96 [0.58-42.2]
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
1/207
1/209
Tau
2
= 0.49, I
2
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
-36% improvement
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
6/43
11/43
Improvement, RR [CI]
Treatment
Control
Li (RCT)
35%
0.65 [0.27-1.39]
8/51
12/50
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
0/38
4/43
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
1/20
2/20
Simonovich (RCT)
4%
0.96 [0.50-1.83]
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
1,399/5,795
1,408/5,763
Gonzalez
-7%
1.07 [0.76-1.50]
60/130
26/60
OT
1
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
16/59
5/15
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
18/80
13/80
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
320 (n)
163 (n)
Bégin (RCT)
-13%
1.13 [0.88-1.45]
156/625
69/313
CAPSID
Körper (RCT)
37%
0.63 [0.33-1.22]
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
7/60
12/60
Raad
-240%
3.40 [2.29-5.02]
284 (n)
3,682 (n)
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
15/98
4/46
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
68 (n)
66 (n)
Tau
2
= 0.04, I
2
= 51.1%, p = 0.52
Late treatment
-4%
1.04 [0.92-1.18]
2,285/10,917
2,134/13,391
-4% improvement
All studies
-5%
1.05 [0.93-1.19]
2,298/11,670
2,144/14,146
-5% improvement
38 convalescent plasma COVID-19 mortality results
c19
early.org/cp Jan 2023
Tau
2
= 0.04, I
2
= 48.4%, p = 0.46
1
OT: comparison with other treatment
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Libster (DB RCT)
50%
0.50 [0.09-2.65]
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-163%
2.63 [0.43-9.10]
5/28
2/30
Gharbharan (DB RCT)
67%
0.33 [0.01-8.16]
0/207
1/209
Tau
2
= 0.30, I
2
= 22.8%, p = 1.
Early treatment
0%
1.00 [0.28-3.54]
7/315
7/319
0% improvement
Agarwal (RCT)
1%
0.99 [0.54-1.81]
19/227
19/224
Improvement, RR [CI]
Treatment
Control
Bajpai (RCT)
-221%
3.21 [0.38-27.4]
3/14
1/15
AlQahtani (RCT)
33%
0.67 [0.22-2.01]
4/20
6/20
CAPRI
Hsue (DB RCT)
-425%
5.25 [0.27-102]
2/16
0/18
DAWn-plasma
Devos (RCT)
-8%
1.08 [0.65-1.80]
320 (n)
163 (n)
TSUNAMI
Menichetti (RCT)
-4%
1.04 [0.62-1.75]
25/231
25/240
Holm (RCT)
69%
0.31 [0.01-7.09]
0/17
1/14
PennCCP2
Bar (RCT)
51%
0.49 [0.18-1.30]
5/40
10/39
PROTECT-Patient
van den Berg (RCT)
67%
0.33 [0.04-3.04]
1/52
3/51
CCAP-2
Thorlaci.. (DB RCT)
-37%
1.37 [0.29-6.52]
6/94
2/43
Denkinger (RCT)
-2%
1.02 [0.59-1.77]
19/68
18/66
Tau
2
= 0.00, I
2
= 0.0%, p = 0.87
Late treatment
2%
0.98 [0.76-1.25]
84/1,099
85/893
2% improvement
All studies
2%
0.98 [0.77-1.25]
91/1,414
92/1,212
2% improvement
14 convalescent plasma COVID-19 mechanical ventilation results
c19
early.org/cp Jan 2023
Tau
2
= 0.00, I
2
= 0.0%, p = 0.89
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Libster (DB RCT)
67%
0.33 [0.07-1.60]
2/80
6/80
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.17
Early treatment
67%
0.33 [0.07-1.60]
2/80
6/80
67% improvement
DAWn-plasma
Devos (RCT)
0%
1.00 [0.74-1.34]
320 (n)
163 (n)
Improvement, RR [CI]
Treatment
Control
Sullivan (DB RCT)
25%
0.75 [0.17-3.32]
3/592
4/589
Jalili (RCT)
-8%
1.08 [0.72-1.63]
27/60
25/60
CCAP-2
Thorlaci.. (DB RCT)
-31%
1.31 [0.45-3.82]
12/89
4/39
Tau
2
= 0.00, I
2
= 0.0%, p = 0.81
Late treatment
-3%
1.03 [0.82-1.30]
42/1,061
33/851
-3% improvement
All studies
-1%
1.01 [0.80-1.27]
44/1,141
39/931
-1% improvement
5 convalescent plasma COVID-19 ICU results
c19
early.org/cp Jan 2023
Tau
2
= 0.00, I
2
= 0.0%, p = 0.96
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Korley (RCT)
10%
0.90 [0.64-1.26]
hosp.
51/257
56/254
Improvement, RR [CI]
Treatment
Control
Alemany (DB RCT)
-5%
1.05 [0.60-1.84]
hosp.
22/188
21/188
Gharbharan (DB RCT)
39%
0.61 [0.28-1.34]
hosp.
10/207
18/209
Tau
2
= 0.00, I
2
= 0.0%, p = 0.39
Early treatment
11%
0.89 [0.68-1.16]
83/652
95/651
11% improvement
Bajpai (RCT)
25%
0.75 [0.55-1.04]
hosp. time
14 (n)
15 (n)
Improvement, RR [CI]
Treatment
Control
AlQahtani (RCT)
22%
0.78 [0.57-1.07]
hosp. time
20 (n)
20 (n)
Pouladza.. (SB RCT)
-30%
1.30 [0.99-1.71]
hosp. time
30 (n)
30 (n)
PLACOVID
Sekine (RCT)
-67%
1.67 [0.01-470]
hosp. time
80 (n)
80 (n)
Holm (RCT)
-62%
1.62 [0.76-3.46]
hosp. time
17 (n)
14 (n)
Sullivan (DB RCT)
54%
0.46 [0.26-0.80]
hosp.
17/592
37/589
Jalili (RCT)
-10%
1.10 [0.89-1.36]
hosp. time
60 (n)
60 (n)
CORIPLASM
Lacombe (RCT)
-7%
1.07 [0.00-9700]
hosp. time
60 (n)
60 (n)
Tau
2
= 0.07, I
2
= 62.6%, p = 0.57
Late treatment
7%
0.93 [0.72-1.20]
17/873
37/868
7% improvement
All studies
8%
0.92 [0.75-1.11]
100/1,525
132/1,519
8% improvement
11 convalescent plasma COVID-19 hospitalization results
c19
early.org/cp Jan 2023
Tau
2
= 0.04, I
2
= 51.0%, p = 0.38
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Tau
2
= 0.49, I
2
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
-36% improvement
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
Improvement, RR [CI]
Treatment
Control
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
death
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
Gonzalez
-7%
1.07 [0.76-1.50]
death
60/130
26/60
OT
1
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
death
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
Bégin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CAPSID
Körper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
death
7/60
12/60
Raad
-240%
3.40 [2.29-5.02]
death
284 (n)
3,682 (n)
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
Tau
2
= 0.04, I
2
= 51.1%, p = 0.52
Late treatment
-4%
1.04 [0.92-1.18]
2,285/10,917
2,134/13,391
-4% improvement
All studies
-5%
1.05 [0.93-1.19]
2,298/11,670
2,144/14,146
-5% improvement
38 convalescent plasma COVID-19 serious outcomes
c19
early.org/cp Jan 2023
Tau
2
= 0.04, I
2
= 48.4%, p = 0.46
Effect extraction pre-specified
(most serious outcome)
1
OT: comparison with other treatment
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Alemany (DB RCT)
-5%
1.05 [0.85-1.30]
no recov.
188 (n)
188 (n)
Improvement, RR [CI]
Treatment
Control
Gharbharan (DB RCT)
-1%
1.01 [0.88-1.16]
no recov.
137/207
137/209
Tau
2
= 0.00, I
2
= 0.0%, p = 0.73
Early treatment
-2%
1.02 [0.91-1.15]
137/395
137/397
-2% improvement
Gharbharan (RCT)
12%
0.88 [0.49-1.60]
no disch.
43 (n)
43 (n)
Improvement, RR [CI]
Treatment
Control
RECOVERY
Recovery Co.. (RCT)
-1%
1.01 [0.97-1.06]
no disch.
1,963/5,795
1,941/5,763
CAPSID
Körper (RCT)
16%
0.84 [0.62-1.14]
no recov.
30/53
35/52
PROTECT-Patient
van den Berg (RCT)
-3%
1.03 [0.62-1.71]
no disch.
18/46
19/50
Rojas (SB RCT)
38%
0.62 [0.40-0.97]
no disch.
46 (n)
45 (n)
Tau
2
= 0.01, I
2
= 32.3%, p = 0.31
Late treatment
8%
0.92 [0.79-1.08]
2,011/5,983
1,995/5,953
8% improvement
All studies
0%
1.00 [0.95-1.05]
2,148/6,378
2,132/6,350
0% improvement
7 convalescent plasma COVID-19 recovery results
c19
early.org/cp Jan 2023
Tau
2
= 0.00, I
2
= 2.1%, p = 1.
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Alemany (DB RCT)
-4%
1.04 [0.97-1.11]
viral load
188 (n)
188 (n)
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.33
Early treatment
-4%
1.04 [0.97-1.11]
0/188
0/188
-4% improvement
Li (RCT)
76%
0.24 [0.07-0.64]
viral+
4/26
15/23
Improvement, RR [CI]
Treatment
Control
Agarwal (RCT)
28%
0.72 [0.55-0.95]
viral+
56/173
76/169
Bajpai (RCT)
32%
0.68 [0.42-1.09]
viral load
14 (n)
15 (n)
Rojas (SB RCT)
-25%
1.25 [0.36-4.33]
viral+
46 (n)
45 (n)
Tau
2
= 0.08, I
2
= 49.7%, p = 0.033
Late treatment
36%
0.64 [0.42-0.97]
60/259
91/252
36% improvement
All studies
25%
0.75 [0.52-1.07]
60/447
91/440
25% improvement
5 convalescent plasma COVID-19 viral clearance results
c19
early.org/cp Jan 2023
Tau
2
= 0.10, I
2
= 77.9%, p = 0.11
Favors conv. plasma
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Libster (DB RCT)
50%
0.50 [0.09-2.65]
death
2/80
4/80
Improvement, RR [CI]
Treatment
Control
Balcells (RCT)
-247%
3.47 [0.35-11.9]
death
5/28
2/30
Korley (RCT)
-396%
4.96 [0.58-42.2]
death
5/250
1/248
Alemany (DB RCT)
80%
0.20 [0.01-4.14]
death
0/188
2/188
Gharbharan (DB RCT)
-1%
1.01 [0.06-16.0]
death
1/207
1/209
Tau
2
= 0.49, I
2
= 30.4%, p = 0.6
Early treatment
-36%
1.36 [0.44-4.17]
13/753
10/755
-36% improvement
Gharbharan (RCT)
4%
0.96 [0.25-2.41]
death
6/43
11/43
Improvement, RR [CI]
Treatment
Control
Li (RCT)
35%
0.65 [0.27-1.39]
death
8/51
12/50
Avendaño-Solà (RCT)
88%
0.12 [0.01-2.11]
death
0/38
4/43
Agarwal (RCT)
-7%
1.07 [0.73-1.58]
death
34/235
31/229
Bajpai (RCT)
-323%
4.23 [0.43-41.6]
death
3/14
1/15
AlQahtani (RCT)
50%
0.50 [0.05-5.08]
death
1/20
2/20
Simonovich (RCT)
4%
0.96 [0.50-1.83]
death
25/228
12/105
Ray (RCT)
33%
0.67 [0.30-1.50]
death
10/40
14/40
RECOVERY
Recovery Co.. (RCT)
0%
1.00 [0.93-1.07]
death
1,399/5,795
1,408/5,763
Pouladza.. (SB RCT)
40%
0.60 [0.16-2.29]
death
3/30
5/30
Bennett-.. (DB RCT)
19%
0.81 [0.36-1.86]
death
16/59
5/15
PLACOVID
Sekine (RCT)
-38%
1.38 [0.73-2.63]
death
18/80
13/80
CAPRI
Hsue (DB RCT)
-212%
3.12 [0.14-71.7]
death
1/16
0/18
DAWn-plasma
Devos (RCT)
1%
0.99 [0.52-1.88]
death
320 (n)
163 (n)
Bégin (RCT)
-13%
1.13 [0.88-1.45]
death
156/625
69/313
CAPSID
Körper (RCT)
37%
0.63 [0.33-1.22]
death
11/53
17/52
TSUNAMI
Menichetti (RCT)
23%
0.77 [0.39-1.49]
death
14/231
19/240
Holm (RCT)
45%
0.55 [0.11-2.84]
death
2/17
3/14
CONTAIN COVID-19
Ortigoza (DB RCT)
12%
0.88 [0.63-1.20]
death
59/462
71/462
PennCCP2
Bar (RCT)
81%
0.19 [0.04-0.84]
death
40 (n)
39 (n)
Sullivan (DB RCT)
86%
0.14 [0.01-2.75]
death
0/592
3/589
Jalili (RCT)
-45%
1.45 [0.74-2.87]
death
16/60
11/60
Baldeón (DB RCT)
12%
0.88 [0.37-2.11]
death
7/63
12/95
PROTECT-Patient
van den Berg (RCT)
17%
0.83 [0.41-1.68]
death
11/52
13/51
De Santis (RCT)
13%
0.87 [0.48-1.56]
death
11/36
25/71
Rojas (SB RCT)
-220%
3.20 [0.64-16.0]
death
46 (n)
45 (n)
COOP-COVID-19-MCTI
Song (RCT)
-52%
1.52 [0.70-3.27]
death
22/87
7/42
CORIPLASM
Lacombe (RCT)
49%
0.51 [0.20-1.32]
death
7/60
12/60
CCAP-2
Thorlaci.. (DB RCT)
-76%
1.76 [0.62-5.01]
death
15/98
4/46
REMAP-CAP
Higgins (RCT)
1%
0.99 [0.86-1.14]
death
370/944
324/790
ICU patients
Denkinger (RCT)
8%
0.92 [0.75-1.11]
death
68 (n)
66 (n)
Tau
2
= 0.00, I
2
= 0.0%, p = 0.81
Late treatment
1%
0.99 [0.94-1.04]
2,225/10,503
2,108/9,649
1% improvement
All studies
1%
0.99 [0.95-1.05]
2,238/11,256
2,118/10,404
1% improvement
36 convalescent plasma COVID-19 Randomized Controlled Trials
c19
early.org/cp Jan 2023
Tau
2
= 0.00, I
2
= 0.0%, p = 0.84
Effect extraction pre-specified
(most serious outcome)
Favors conv. plasma
Favors control